The US Federal Trade Commission (FTC) has issued a policy statement indicating its intent to rigorously investigate improper listings in the Food and Drug Administration’s (FDA) Orange Book, a public record of approved drugs with therapeutic equivalence evaluations. In a move aimed at maintaining the integrity of the Orange Book, the FTC has warned drug manufacturers about the consequences of inappropriately listing patents that cannot meet the statutory listing criteria.
An official notice published on the website of law firm Axinn, Veltrop & Harkrider LLP, mentions this FTC policy statement. According to it, the FTC is on a mission “to take actions against companies and individuals that improperly list patents in the Orange Book” and to “use its full legal authority”. This development represents a firm stance by the regulatory body and underscores their dedication to protecting consumers from potentially harmful medications being listed and sold.
As a crucial reference for healthcare professionals, the Orange Book lists all drugs that the FDA has deemed safe and effective. It also includes patent and exclusivity information, providing a constraint on competition until patent expiration. Therefore, an improper listing not only breaches the law, but it could also mislead healthcare professionals, result in patients receiving substandard or unauthorized medication, and stifle fair competition in the pharmaceutical sector.
The FTC’s recent policy statement infers a readiness to enforce strict scrutiny to ensure the validity of listings, holding both drug manufacturers and individuals accountable. It’s a clear message to the pharmaceutical industry to uphold the highest standards and avoid unscrupulous practices, as consequences under FTC’s full legal authority might carry severe implications.
Legal professionals in the pharmaceutical industry should be aware of this shift in the regulatory landscape and advise their clients accordingly. Particularly for manufacturers, this increased scrutiny necessitates a thorough review and accurate maintenance of their patent listings in the Orange Book. Let us all embrace the ethos of integrity, following all statutory requirements to protect consumers’ health and safety and maintain an honest and competitive pharmaceutical marketplace.
For more detailed information, here is the original legal notice.